NJ State Employees Deferred Compensation Plan’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,000	Closed	-$1.61M	–	493
2023 Q1	$1.61M	Buy	15,000 +11,000	+275%	+$1.27M	0.25%	97
2022 Q4	$440K	Buy	+4,000	New	+$259K	0.07%	289

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's RXDX Position: Q2 2023 in Review

NJ State Employees Deferred Compensation Plan sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 15,000 shares — an estimated $1.61M sold.

NJ State Employees Deferred Compensation Plan first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.61M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

NJ State Employees Deferred Compensation Plan reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 15,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.61M.
NJ State Employees Deferred Compensation Plan first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
NJ State Employees Deferred Compensation Plan's Prometheus Biosciences, Inc. Common Stock position peaked at $1.61M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q2 2023, filed 2 Aug 2023.